¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"fine structure mapping"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • gene mapping
    À¯ÀüÀÚÀ§Ä¡ÁöÁ¤, À¯ÀüÀÚÁöµµÀÛ¼º
  • MR mapping
    ÀÚ±â°ø¸íÁöµµÈ­
  • mapping
    ÁöµµÈ­, ÁöµµÀÛ¼º
  • spot mapping
    ȯÀڹ߻ýÁöµµÀÛ¼º
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • bone structure
    »À±¸Á¶, °ñ±¸Á¶
  • chain structure
    »ç½½±¸Á¶, ¿¬¼â±¸Á¶
  • cognitive structure
    ÀÎÁö±¸Á¶
  • core structure
    Á߽ɱ¸Á¶¹°
  • decidual structure
    Å»¶ô¸·±¸Á¶
  • discoid structure
    ¿ø¹Ý±¸Á¶
  • electron structure
    ÀüÀÚ±¸Á¶
  • immunoglobulin structure
    ¸é¿ª±Û·ÎºÒ¸°±¸Á¶
  • structure activity relationship
    ±¸Á¶È°¼º»ó°ü°ü°è, ±¸Á¶ÀÛ¿ë°ü°è
  • structure
    ±¸Á¶
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • quasicrystalline structure
    ÁذáÁ¤±¸Á¶(ñÞÌ¿ïÜϰðã).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • fine horizontal linear opacity
    ¹Ì¼¼ÇÑ ¼öÆò¸éÇü ¼±»ó ºÒÅõ¸íü
  • fine injection
    ¹Ì¼¼¸Æ°üÁÖ»ç.
  • fine needle
    ¹Ì¼¼Ä§
  • fine needle aspiration
    ¹Ì¼¼Ä§ ÈíÀÎ
  • fine needle aspiration biopsy
    ¹Ì¼¼Ä§ ÈíÀÎ »ý°Ë¼ú
  • fine needle aspiration biopsy
    ¼¼Ä§¿¡ ÀÇÇÑ ÈíÀÔ»ý°Ë¼ú
  • fine needle aspiration cytology
    ¹Ì¼¼Ä§ ÈíÀμ¼Æ÷°Ë»ç¹ý
  • fine needle puncture
    ¹Ì¼¼Ä§ õÀÚ
  • fine powder
    ¼¼¸»(á¬ØÇ), °¡´ÂºÐ¸».
  • fine tremor
    ¹Ì¼ÒÁøÀü(Ú°á³òèïµ).
  • fine-needle aspiration
    ¼¼Ä§ ÈíÀÎ (á¬öÜ ýåìÚ), °¡´Â ¹Ù´Ã ÈíÀÎ (ýåìÚ)
  • fine-needle puncture
    ¼¼Ä§ õÀÚ (á¬öÜ ô¾í©), °¡´Ã ¹Ù´Ã õÀÚ (ô¾í©)
  • percutaneous fine needle aspiration
    °æÇÇÀû ¹Ì¼¼Ä§ÈíÀμú
  • alveolar structure
    Æ÷»ó±¸Á¶(¡­Ï°ðã).
  • alveolar structure
    ÆóÆ÷±¸Á¶(¡­Ï°ðã)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • eye structure
    ´« ±¸Á¶ (ϰðã)
  • Greek-key structure
    ±×¸®½º¿­¼è ±¸Á¶(ϰðã)
  • isodesmic structure
    ÀÌÁúµ¿°áÇÕ ±¸Á¶(ì¶òõÔÒÌ¿ùêϰðã)
  • L-shaped structure
    L-Çü(úþ)±¸Á¶(ϰðã)
  • L-type structure
    L-Çü(úþ)±¸Á¶(ϰðã)
  • membrane structure
    ¸·±¸Á¶(دϰðã)
  • noncovalent structure
    ºñ°ø À¯±¸Á¶(ÞªÍëêóϰðã)
  • primary structure
    ÀÏÂ÷±¸Á¶(ìéó­Ï°ðã)
  • protein structure
    ´Ü¹éÁú ±¸Á¶(Ó±ÛÜòõϰðã)
  • quaternary structure
    »çÂ÷(ÞÌó­) ±¸Á¶(ϰðã).
  • quinary structure
    ¿ÀÂ÷(çéó­) ±¸Á¶(ϰðã).
  • secondary structure
    ÀÌÂ÷ ±¸Á¶(ì£ó­Ï°ðã)
  • sigma structure
    ½Ã±×¸¶±¸Á¶(ϰðã)
  • solenoid structure
    ¼Ö·¹³ëÀÌµå ±¸Á¶(ϰðã)
  • super-secondary structure
    ÃÊÀÌÂ÷ ±¸Á¶(õ±ì£ó­Ï°ðã)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • fine needle puncture
    ¹Ì¼¼Ä§ÃµÀÚ
  • percutaneous fine needle aspiration
    °æÇÇÀû¹Ì¼¼Ä§ÈíÀμú
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
HCG, hCG Human Chorionic Gonadotropin; »ç¶÷À¶¸ð¼º¼º¼±ÀÚ±ØÈ£¸£¸ó
  1. Placental Glycoprotein Hormone
&nbs...
hfs hyperfine structure
LFS lateral facet syndrome; Li-Fraumeni syndrome; limbic forebrain structure; liver function series
MTS Medicare transaction system; magnetization transfer contrast; methotrexate; multicellular tumor sphe...
QSAR quantitative structure-activity relationship
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
SPM96 Statistical Parametric Mapping
CM consistent mapping
CASE Computer Automated Structure Evaluation
DLS Dimer Linkage Structure
FNA Fine Needle Aspiration
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • atomic structure
    ¿øÀÚ ±¸Á¶
  • bone structure
    °ñ°Ý, »À ±¸Á¶, °ñ ±¸Á¶
    µ¿¹°ÀÇ ¸öÀ» ÁöÅÊÇϰí üÇüÀ» Çü¼ºÇÏ´Â ±â°ü. ü°Ý ¶Ç´Â ÀÚ¼¼¸¦ ÁöÅÊÇϸç, ¿îµ¿ÀÇ Åä´ë°¡ µÇ°í, ³»ÀåÀÇ ¸ðµç ±â°üÀ» º¸È£ÇÏ´Â ¿ªÇÒÀ» ÇÑ´Ù. ôÃßµ¿¹°¿¡¼­´Â ±âº»ÀûÀ¸·Î °ñ°Ý¿¡ °øÅëÁ¡ÀÌ Àִµ¥, µÎ°ñ°ú ôÃß°¡ Áß½ÉÀ» ÀÌ·ç¸ç, °Å±â¿¡ »çÁö°ñÀÌ À̾îÁø´Ù. µ¿¹°ÀÇ Á¾·ù¿¡ µû¶ó¼­ °ñ°ÝÀÇ Çü»óÀ̳ª ¼ö·® µî¿¡´Â Â÷À̰¡ ÀÖ´Ù. °ñ°ÝÀÇ °áÇÕ ¹æ¹ý¿¡´Â ´ÙÀ½ÀÇ 3Á¾·ù°¡ ÀÖ´Ù. ¨ç °üÀý °áÇÕ : °ñ°ÝÀÇ ´ëºÎºÐÀº °üÀý·Î¼­ ¿òÁ÷À̵µ·Ï µÇ¾î ÀÖ´Ù. ¨è ºÀÇÕ : µÎ°³°ñÀº °ñ°ÝÀÇ °áÇպκÐÀÌ Åé´Ïó·³ µÇ¾î ÀÖ¾î Åé´Ï¹ÙÄû¸¦ ¸ÂÃá µíÀÌ °áÇյǾî ÀÖ´Ù. ¨é ¿¬°ñ °áÇÕ : Á¿ìÀÇ Ä¡°ñÀ̳ª ôÃß°ñ »çÀÌ¿¡´Â ¿¬°ñ Á¶Á÷ÀÌ ÀÖ¾î ±×°ÍÀÌ °ñ°Ý°ú °ñ°ÝÀ» °áÇÕ½ÃŲ´Ù.
  • capsule structure
    ³¶ ±¸Á¶, °üÀý³¶ ±¸Á¶
  • chain structure
    ¿¬¼â ±¸Á¶
  • chemical structure
    È­ÇÐ ±¸Á¶
  • cubic structure
    µî¹æ ±¸Á¶, ÀÔ¹æ ±¸Á¶
  • decidua structure
    Å»¶ô¸· ±¸Á¶
  • diencephalic structure
    °£³ú ±¸Á¶
  • domain structure
    ¿µ¿ª ±¸Á¶
  • electron structure of atom
    ¿øÀÚÀÇ ÀüÀÚ ±¸Á¶
  • encapsulated structure
    Çdz¶ ±¸Á¶
  • extracranial structure
    µÎ°³¿Ü ±¸Á¶¹°
  • locomotor structure
    ¿îµ¿ ±¸Á¶¹°
  • monoclinic structure
    ´Ü»ç ±¸Á¶
  • mosaic structure
    ¸ðÀÚÀÌÅ© ±¸Á¶
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
chromosome mapping The mapping of the relative locations of genes on a chromosome by analysing linkage frequencies (how often different genes are inherited together) and crossover frequencies (how often different combinations of three or more genes are inherited) or recombination frequencies.
(09 Oct 1997)
S1 nuclease mapping A method for locating the 5' end of a transcript in a mixture of RNA.
(05 Mar 2000)
heteroduplex mapping <molecular biology> Heteroduplex mapping is a lab technique used to locate a particular sequence of nucleotides. It involves making a heteroduplex by pairing the unknown nucleic acid strand with a reference strand which has a known sequence.
(09 Oct 1997)
nucleotide mapping Two-dimensional separation and analysis of nucleotides.
(12 Dec 1998)
epitope mapping Methods used for studying the interactions of antibodies with specific regions of protein antigens. Important applications of epitope mapping are found within the area of immunochemistry.
(12 Dec 1998)
brush heap structure Haphazard interlocking of fibrils in a gel or hydrocolloid impression material.
(05 Mar 2000)
gel structure Brush heap structure of fibrils giving firmness to hydrocolloids.
(05 Mar 2000)
chi structure <molecular biology> The name for the X-shaped structure which forms during the recombination process between two plasmids, or circular pieces, of DNA. The Greek letter chi resembles this structure.
(05 Jan 1998)
group structure The informal or formal organization of a group of people based on a network of personal relationships which is influenced by the size and composition, etc., of the group.
(12 Dec 1998)
molecular structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number and location of chemical bonds.
(12 Dec 1998)
cointegrate structure A structure of DNA produced by the fusion of two replicons, one possessing a transposon.
(05 Mar 2000)
cruciform structure A structure, shaped like a cross, which can form during homologous recombination when inverted base-pair repeats pair with each other on the same strand of DNA instead of with homologous sections on a different strand of DNA.
(09 Oct 1997)
crystal structure <chemistry> The configuration in which atoms are arranged in a material. These arrangements have a direct effect on the physical properties of the material. These arrangements commonly take the form of cubes, rectangular solids, hexagonal solids. Etc.
(05 Aug 1998)
primary structure The covalent backbone of a macromolecule. The order of subunits in a biological polymer, such as amino acids in a polypeptide or nucleotides in a molecule of DNA or RNA.
(09 Oct 1997)
protein structure The amino acids and their manner of arrangement in constituting a protein. The four stages of protein structuring are primary (protein structure, primary see amino acid sequence), secondary (protein structure, secondary), tertiary (protein structure, tertiary), and quaternary (protein structure, quaternary see protein conformation).
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • fine ceramics
    ÆÄÀÎ ¼¼¶ó¹Í½º
  • fine champagne
    Çɼ§ÆÄ´º
  • fine chemical
    Á¤Á¦ È­ÇÐ Á¦Ç°;Á¤¾àǰ
  • fine chemistry
    ºÎ°¡°¡Ä¡ È­ÇÐ Á¦Ç°¿¡ °üÇÑ È­ÇÐ
  • fine cut
    °¡´Ã°Ô ½ã ´ã¹è
  • fine food
    Á¤¹Ð ½Äǰ;°íºÎ°¡°¡Ä¡ ½Äǰ
  • fine print
    ÀÛÀº ȰÀÚ;ÀÛÀº ±ÛÀÚ ºÎºÐ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á